TLDR Targeting the IL-23/IL-17 pathway effectively treats several inflammatory skin diseases.
The IL-23/IL-17 pathway played a crucial role in the pathogenesis of various inflammatory skin diseases, including psoriasis, atopic dermatitis, hidradenitis suppurativa, alopecia areata, pityriasis rubra pilaris, pemphigus, and systemic sclerosis. IL-17, primarily secreted by Th17 cells, was stimulated by IL-23. Clinical trials demonstrated that monoclonal antibodies targeting IL-23, IL-17, and tumor necrosis factor were effective treatments for these conditions. The document summarized the biology, signaling, and pathophysiological functions of the IL-23/IL-17 axis and discussed the available biologics targeting this pathway.
20 citations,
December 2019 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.
62 citations,
June 2015 in “The Journal of Dermatology” People with alopecia areata have more Th17 cells and fewer Treg cells, which may be key to the condition's development.
60 citations,
September 2015 in “Expert Review of Clinical Immunology” Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.
191 citations,
May 2018 in “British journal of dermatology/British journal of dermatology, Supplement” Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.
1 citations,
January 2023 in “International Journal of Molecular Sciences” Understanding how Regulatory T Cells work could help create treatments for certain skin diseases and cancers.
124 citations,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
15 citations,
January 2022 in “Immune Network/Immune network” New targeted immunotherapies are improving treatment for inflammatory skin diseases.
